India - English - Central Drugs Standard Control Organization

kaleon lab. - tab - 10

Bangladesh - English - DGDA (Directorate General of Drug Administration)

beximco pharmaceuticals ltd. - vitamin c - tablet - 250 mg

Philippines - English - FDA (Food And Drug Administration)

progen pharmaceutical distributors; distributor: progen pharmaceutical distributors - caspofungin (as acetate) - lyophilized powder for solution for infusion - 50mg

India - English - Central Drugs Standard Control Organization

glenmark - diphenhydramine hcl.,bromhexine hcl.,guaiphenesin,amm.chl.,menthol - syr - 8,4,50,100,1;mg;5ml - 100 ml

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

salbutamol 2mg, bromhexine hcl 4mg, guaifenesin 100mg, menthol 1mg/1ml

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

salbutamol sulphate 2mg,bromhexine hcl 4mg,guaifensin usp 100mg,menthol 1mg/100ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

aksim laboratories (ayurvedic) - aswagandharista - liquid

Bangladesh - English - DGDA (Directorate General of Drug Administration)

neuron drug laboratories (unani) - sharbat buzuri - liquid

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - calcipotriene hydrate (unii: s7499tyy6g) (calcipotriene - unii:143nq3779b), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - calcipotriene 50 ug in 1 g - taclonex® (calcipotriene and betamethasone dipropionate) ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older for up to 4 weeks. - taclonex® ointment should not be applied to the face, axillae or groin. - taclonex® ointment should not be used if there is skin atrophy at the treatment site. none. teratogenic effects: pregnancy category c there are no adequate and well-controlled studies in pregnant women. pregnant women were excluded from the clinical studies conducted with taclonex® ointment. taclonex® ointment should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. animal reproduction studies have not been conducted with taclonex® ointment. taclonex® ointment contains calcipotriene that has been shown to be fetotoxic and betamethasone dipropionate that has been shown to be teratogenic in animals when given systemically. teratogenicity studies with calcipotriene were performed by the